Skip to main content

Table 1 Demographics and baseline characteristics of the study population*

From: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

 

CMA (n = 47)

Placebo (n = 22)

P value

Age (years)

70.77 ± 8

70.91 ± 7.54

0.97

Gender

Male

25 (53.2%)

11 (50%)

0.88

Female

22 (46.8%)

11 (50%)

 

Ethnicity

Caucasian (100%)

Caucasian (100%)

–

Body Mass Index

29.04 ± 5.25

27.43 ± 5.05

0.23

ADCS-ADL

55.79 ± 15.02

56.67 ± 15.63

0.83

ADAS-Cog

22.88 ± 10.51

26.28 ± 17.35

0.32

MMSE

19.45 ± 4.21

17.95 ± 5.66

0.22

CDR

0.82 ± 0.45

1.02 ± 0.6

0.09

  1. * Presented as Mean ± Standard deviation, except for gender and ethnicity
  2. MMSE Mini Mental state examination, ADAS-cog Alzheimer's disease assessment scale-cognitive subscale, ADCS-AD Alzheimer's disease cooperative study—activities of daily Living, CDR Clinical dementia rating scale
Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us